CRISPR Genome Editing Treatment for ATTR – Webinar

Jeffrey Cehelsky of Intellia provides an update on Intellia’s CRISPR/Cas9 genome editing treatment for TTR amyloidosis at ASG’s 12/05/2020 ATTR webinar.